{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:25:44Z","timestamp":1793301944337,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n In 2023, more than 80\u202f000 individuals died from an overdose involving opioids. With almost two-thirds of the US jail population experiencing a substance use disorder, jails present a key opportunity for providing lifesaving treatments, such as medications for opioid use disorder (MOUD).<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To examine the prevalence of MOUD in US jails and the association of jail- and county-level factors with MOUD prevalence using a national sample.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This survey study used a nationally representative cross-sectional survey querying 1028 jails from June 2022 to April 2023 on their provision of substance use disorder treatment services. The survey was conducted via mail, phone, and the internet. County-level data were linked to survey data, and binary logistic regressions were conducted to assess the probability that a jail offered any treatment and MOUD. A stratified random sample of 2791 jails identified by federal lists of all jails in the US was invited to participate. Staff members knowledgeable about substance use disorder services available in the jail completed the survey.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n US Census region, urbanicity, jail size, jail health care model (direct employees or contracted), county opioid overdose rate, county social vulnerability (measured using the Centers for Disease Control and Prevention 2020 Social Vulnerability Index summary ranking, which ranks counties based on 16 social factors), and access to treatment in the county were assessed.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Availability of any type of substance use disorder treatment (eg, self-help meetings), availability of MOUD (ie, buprenorphine, methadone, and naltrexone) to at least some individuals, and availability of MOUD to any individual with an OUD were assessed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 2791 invited jails, 1028 jails participated (36.8% response rate). After merging the sample with county data, 927 jails were included in analysis, representative of 3157 jails nationally after weighting; most were from nonmetropolitan counties (\u202d1756 jails [55.6%; 95% CI, 52.3%-59.0%]) and had contracted health care services (1886 jails [59.7%; 95% CI, 56.5%-63.0%]); fewer than half of these jails (1383 jails [43.8%; 95% CI, 40.5%-47.1%]) offered MOUD to at least some individuals, and 405 jails (12.8%; 95% CI, 10.7% to 14.9%) offered MOUD to anyone with an OUD. Jails located in counties with lower social vulnerability (adjusted odds ratio per 1-percentile increase\u2009=\u20090.28; 95% CI, 0.19-0.40) and shorter mean distances to the nearest facility providing MOUD (adjusted odds ratio per 1-SD increase, 0.80; 95% CI, 0.72-0.88) were more likely to offer MOUD.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and relevance<\/jats:title>\n In this study, few jails indicated offering frontline treatments despite being well positioned to reach individuals with an OUD. These findings suggest that efforts and policies to increase MOUD availability in jails and the surrounding community may be associated with helping more individuals receive treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.34704","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T11:00:45Z","timestamp":1727175645000},"page":"e2434704","source":"Crossref","is-referenced-by-count":58,"title":["Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails"],"prefix":"10.1001","volume":"7","author":[{"given":"Elizabeth","family":"Flanagan Balawajder","sequence":"first","affiliation":[{"name":"Public Health Department, NORC at the University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Ducharme","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Public Health Department, NORC at the University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe A.","family":"Lamuda","sequence":"additional","affiliation":[{"name":"Public Health Department, NORC at the University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marynia","family":"Kolak","sequence":"additional","affiliation":[{"name":"Department of Geography and Geographic Information Science, University of Illinois at Urbana-Champaign"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Friedmann","sequence":"additional","affiliation":[{"name":"Office of Research, Baystate Health and University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold A.","family":"Pollack","sequence":"additional","affiliation":[{"name":"Crown Family School of Social Work, Policy and Practice, University of Chicago, Chicago, Illinois"},{"name":"Department of Public Health Sciences, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Chicago, Chicago, Illinois"},{"name":"Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"issue":"22","key":"zoi241030r2","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2013tackling the opioid-overdose epidemic.","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi241030r3","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.","volume":"24","author":"Ma","year":"2019","journal-title":"Mol Psychiatry"},{"issue":"3","key":"zoi241030r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0558","article-title":"Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid Use.","volume":"1","author":"Winkelman","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi241030r6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/add.15640","article-title":"Jail and overdose: assessing the community impact of incarceration on overdose.","volume":"117","author":"Victor","year":"2022","journal-title":"Addiction"},{"issue":"2","key":"zoi241030r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi241030r9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40352-023-00209-w","article-title":"Medications for opioid use disorder during incarceration and post-release outcomes.","volume":"11","author":"Cates","year":"2023","journal-title":"Health Justice"},{"issue":"13","key":"zoi241030r10","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders.","volume":"374","author":"Lee","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi241030r11","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s11606-022-07812-x","article-title":"Availability of medications for opioid use disorder in U.S. jails.","volume":"38","author":"Sufrin","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi241030r13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40352-022-00197-3","article-title":"Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S.","volume":"10","author":"Scott","year":"2022","journal-title":"Health Justice"},{"issue":"2S Suppl 1","key":"zoi241030r16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update.","volume":"14","year":"2020","journal-title":"J Addict Med"},{"issue":"1","key":"zoi241030r19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40352-021-00137-7","article-title":"The compendium of U.S. jails: creating and conducting research with the first comprehensive contact database of U.S. jails.","volume":"9","author":"Foudray","year":"2021","journal-title":"Health Justice"},{"issue":"1","key":"zoi241030r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44369","article-title":"Availability of medications for the treatment of opioid use disorder among pregnant and postpartum individuals in US jails.","volume":"5","author":"Sufrin","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi241030r28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","article-title":"Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system.","volume":"75","author":"Green","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"zoi241030r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7028","article-title":"Assessment of community-level vulnerability and access to medications for opioid use disorder.","volume":"5","author":"Joudrey","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi241030r31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/00220426221109948","article-title":"Medication-assisted treatment in problem-solving courts: a national survey of state and local court coordinators.","volume":"53","author":"Farago","year":"2023","journal-title":"J Drug Issues"},{"issue":"2","key":"zoi241030r32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0209","article-title":"Accessibility of opioid treatment programs based on conventional vs perceived travel time measures.","volume":"7","author":"Kim","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi241030r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2022.115034","article-title":"Individual, interpersonal, and neighborhood measures associated with opioid use stigma: evidence from a nationally representative survey.","volume":"305","author":"Lin","year":"2022","journal-title":"Soc Sci Med"},{"key":"zoi241030r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107858","article-title":"Estimating the impact of wide scale uptake of screening and medications for opioid use disorder in US prisons and jails.","volume":"208","author":"Macmadu","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi241030r20","volume-title":"Jail Inmates in 2021\u2014Statistical Tables","author":"Zeng","year":"2022"},{"key":"zoi241030r35"},{"key":"zoi241030r1","unstructured":"Ahmad? FB, Cisewski? JA, Rossen? L, Sutton? P. Provisional drug overdose data. National Center for Health Statistics. Accessed June 4, 2024. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi241030r5","unstructured":"Bronson? J, Stroop? J, Zimmer? S, Berzofsky? M. Drug use, dependence, and abuse among state prisoners and jail inmates, 2007-2009. Updated August 10, 2020. Accessed August 19, 2024. https:\/\/bjs.ojp.gov\/content\/pub\/pdf\/dudaspji0709.pdf"},{"key":"zoi241030r7","unstructured":"US Food and Drug Administration. Information about medications for opioid use disorder (MOUD). Accessed October 5, 2023. https:\/\/www.fda.gov\/drugs\/information-drug-class\/information-about-medications-opioid-use-disorder-moud"},{"key":"zoi241030r12","unstructured":"Maruschak? LM, Minton? TD, Zeng? Z. Opioid Use Disorder Screening and Treatment in Local Jails, 2019. Bureau of Justice Statistics. Accessed September 4, 2024. https:\/\/bjs.ojp.gov\/library\/publications\/opioid-use-disorder-screening-and-treatment-local-jails-2019"},{"key":"zoi241030r14","unstructured":"US Office of National Drug Control Policy. National drug control strategy. Accessed September 18, 2023. https:\/\/www.whitehouse.gov\/wp-content\/uploads\/2022\/04\/National-Drug-Control-2022Strategy.pdf"},{"key":"zoi241030r15","unstructured":"US Department of Justice Civil Rights Division. The Americans with Disabilities Act and the opioid crisis: combating discrimination against people in treatment or recovery. Accessed September 18, 2023. https:\/\/archive.ada.gov\/opioid_guidance.pdf"},{"key":"zoi241030r17","unstructured":"US Department of Justice Bureau of Justice Assistance; National Institute of Corrections. Guidelines for Managing Substance Use Withdrawal in Jails. Comprehensive Opioid, Stimulant, and Substance Use Program. Accessed July 8, 2024. https:\/\/www.cossup.org\/Content\/Documents\/JailResources\/Guidelines_for_Managing_Substance_Withdrawal_in_Jails_6-6-23_508.pdf"},{"key":"zoi241030r18","unstructured":"Centers for Medicare & Medicaid Services. HHS releases new guidance to encourage states to apply for new Medicaid reentry section 1115 demonstration opportunity to increase health care for people leaving carceral facilities. Accessed March 28, 2024. https:\/\/www.cms.gov\/newsroom\/press-releases\/hhs-releases-new-guidance-encourage-states-apply-new-medicaid-reentry-section-1115-demonstration"},{"key":"zoi241030r21","unstructured":"University of Illinois at Urbana-Champaign. Opioid Environment Policy Scan. Accessed March 28, 2024. https:\/\/oeps.healthyregions.org\/"},{"key":"zoi241030r22","unstructured":"National Council for Mental Wellbeing. Medication-assisted treatment (mat) for opioid use disorder in jails and prisons: a planning and implementation toolkit. Accessed January 9, 2024. https:\/\/www.thenationalcouncil.org\/resources\/medication-assisted-treatment-mat-for-opioid-use-disorder-in-jails-and-prisons-a-planning-and-implementation-toolkit\/"},{"key":"zoi241030r23","unstructured":"Substance Abuse and Mental Health Services Administration. Find a treatment facility. Accessed March 28, 2024. https:\/\/findtreatment.gov\/"},{"key":"zoi241030r24","unstructured":"National Center for Health Statistics. NCHS urban-rural classification scheme for counties. Accessed August 20, 2024. https:\/\/www.cdc.gov\/nchs\/data_access\/urban_rural.htm"},{"key":"zoi241030r25","unstructured":"Centers for Disease Control and Prevention Agency for Toxic Substances and Disease Registry Geospatial Research, Analysis, and Services Program. CDC\/ATSDR SVI: data and documentation download. Accessed January 4, 2024. https:\/\/www.atsdr.cdc.gov\/placeandhealth\/svi\/data_documentation_download.html"},{"key":"zoi241030r27","unstructured":"Zeng? Z. Jail Inmates in 2022\u2014Statistical Tables. US Department of Justice Office of Justice Programs Bureau of Justice Statistics; 2023. Accessed July 9, 2024. https:\/\/bjs.ojp.gov\/document\/ji22st.pdf"},{"key":"zoi241030r29","unstructured":"National Sheriff\u2019s Association; National Commission on Correctional Health Care. Jail-based medication-assisted treatment: promising practices, guidelines, and resources for the field. Accessed January 9, 2024. https:\/\/www.ncchc.org\/wp-content\/uploads\/Jail-Based-MAT-PPG-web.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2823908\/flanagan_balawajder_2024_oi_241030_1726504342.57277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T11:00:51Z","timestamp":1727175651000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2823908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.34704","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}